News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IMRIS To Hold Second Quarter 2014 Results Conference Call



7/30/2014 8:51:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WINNIPEG, MB and MIINNEAPOLIS, MN, July 29, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM)

Second Quarter 2014 Earnings ReleaseAugust 7, 2014
Conference Call and WebcastAugust 7, 9:00 AM ET
Hosted by Jay D. Miller, President and Chief Executive Officer;
Kelly McNeill, Executive Vice President, Finance & CFO
Participant Numbers 1-866-530-1554 or 1-416-849-1847
Conference Call ID Number 6581167

A question and answer session for analysts and institutional investors will follow management's presentation.

A taped rebroadcast will be available to listeners following the call until 12:00 PM (ET) on August 15, 2014. To access the rebroadcast, please call 1-888-203-1112 and enter access code 6581167.

A live audio webcast will be available on the company's website at www.imris.com.

About IMRIS

IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angio modalities accessed effortlessly in the operating room setting. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular, spinal and cerebrovascular markets and have been selected by 58 leading medical institutions around the world. For more information, visit www.imris.com.

SOURCE IMRIS Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
IMRIS
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES